MÜV and Strainprint™: Revolutionizing Medical Cannabis
MÜV recognizes that one of the biggest barriers of cannabis being widely accepted as medicine is the lack of research. That’s not to say there isn’t anecdotal evidence – a simple Google search of “cannabis success story” yields 17 million results – there is a lack of clinical research.
Despite the fact that medical cannabis has been legal in California since 1996, with more states following in the years after, the federal government has been less welcoming to the movement. Cannabis – labeled “marihuana” on the DEA’s list of controlled substances – is still classified as a Schedule 1 narcotic.
This scheduling severely hinders the ability to conduct sound research on the efficacy of medical cannabis. The most recent example of this to make headlines is that of Sue Sisley, a researcher at the Scottsdale Research Institute. Sisley led the first study on whole-cannabis use for PTSD symptoms – but receiving approval for the study took years. And, to boot, the cannabis obtained for the study (of which there is only one DEA-approved producer) tends to cap at 13% THC according to the Washington Post, though Sisley’s study found the percentage was closer to 8%.
Without research, and accurate research using cannabis with cannabinoid percentages truer to what is available on the market, there can be no conclusive claims made about cannabis. MMTCs in the state of Florida have to rely heavily on patient reporting on their medical cannabis products, making cannabis journaling more imperative than ever.
MÜV and Strainprint™ are committed to making session tracking simpler than ever.
Strainprint™: By Patients, For Patients
Stephanie Karasick had tried everything to help with her depression and anxiety. After years of struggling with traditional pharmaceuticals, Karasick decided to begin a medical cannabis routine. A week into this new path, Karasick noticed her uptick in mood. She also quickly noticed that strains affected her differently. She took detailed notes of how she felt before and after medicating, how many doses it took of the product to achieve the desired effect, and how long the effects lasted.
After journaling and dialing in her own routine, Karasick had a thought – if I can track every step I take with a smart watch, why isn’t there a solution for tracking my medical cannabis results?
Karasick took this question and developed Strainprint, the first medical cannabis journaling app created by patients, for patients with the ultimate goal of bringing data to the medical cannabis space.
How will it benefit my medical cannabis routine?
Strainprint is the ultimate tool for medical cannabis patients. All data is made anonymous within the app, and is securely stored using military-grade encryption for patient protection.
Upon registering with code MUVFL, patients are prompted to indicate the ailment they are seeking to treat from a detailed list, and from there the symptoms experienced as a result of the ailment. Patients can indicate as many ailments and symptoms as necessary for the most detailed tracking.
By using code MUVFL at signup, patients will be able to quickly search for the MÜV Products current to their regimen and add to the “My Products” function, located on the home screen of Strainprint.
Tracking is where the true benefit of Strainprint lies. After clicking “Track Session” on the home screen, patients will:
- Indicate the symptom(s) they are seeking to ease
- Indicate the severity of symptom(s) on a scale of 1-10
- Select the MÜV strain/product being used (populated from “My Products”)
- Record the dosage used (1 puff of vape, 1 dropper of tincture, etc.)
- After 20 minutes (or more, depending on method of consumption), Strainprint™ notifies the patient to record how they feel after the medication has taken effect.
After tracking sessions, patients can use the “Snapshot” function for an overview of the sessions tracked for specific symptoms. Clicking into the symptom ranks the products in order from most effective to least for that symptom, lending valuable insights to symptom management.
The “Explore” function allows patients to discover strains by symptom, effect, or what is trending in use. This data is anonymously aggregated through tracked sessions from all users in Strainprint™, allowing patients to view the strains or products most effective for others with the same conditions or symptoms.
Be the Research
Strainprint™ gives patients the power to take control of their symptom management; to identify the products that work best for their individual needs. Not only that, the anonymized data helps patients make informed decisions on the best products to add to their routine.
This data collection has been leveraged by Washington State University for two separate studies. The first found that cannabis can reduce headache and migraine severity by almost 50%, the second that cannabis can alleviate “short-term levels of depression, anxiety, and stress.” The data collection and studies conducted with it will truly revolutionize the medical cannabis space.
MÜV is asking you, our patients, to be pioneers in cannabis research. To track medicating sessions to not only learn about your medical cannabis routine, but to help bring this much-needed data to further legitimize (and destigmatize) cannabis as a medical treatment option.
The Patient Pioneer Program
Each month, MÜV features strains as part of the Patient Pioneer Program. Patients that track any one of these strains within the Strainprint five times will receive a 10% (not stackable) discount on their next purchase. MÜV Patients are eligible to track two strains per month to help further our knowledge of medical cannabis and its benefits for symptom management.